BR112021023563A2 - Sais farmaceuticamente aceitáveis de [2-(3-fluoro-5-metano-sulfonilfenóxi)etil](propil) amina e usos dos mesmos - Google Patents

Sais farmaceuticamente aceitáveis de [2-(3-fluoro-5-metano-sulfonilfenóxi)etil](propil) amina e usos dos mesmos

Info

Publication number
BR112021023563A2
BR112021023563A2 BR112021023563A BR112021023563A BR112021023563A2 BR 112021023563 A2 BR112021023563 A2 BR 112021023563A2 BR 112021023563 A BR112021023563 A BR 112021023563A BR 112021023563 A BR112021023563 A BR 112021023563A BR 112021023563 A2 BR112021023563 A2 BR 112021023563A2
Authority
BR
Brazil
Prior art keywords
methanesulfonylphenoxy
fluoro
propyl
amine
ethyl
Prior art date
Application number
BR112021023563A
Other languages
English (en)
Inventor
Clas Sonesson
Inese Reine
Mihkel Tedroff Joakim
Nicholas Waters Ross
Original Assignee
Integrative Res Laboratories Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrative Res Laboratories Sweden Ab filed Critical Integrative Res Laboratories Sweden Ab
Publication of BR112021023563A2 publication Critical patent/BR112021023563A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

sais farmaceuticamente aceitáveis de [2-(3-fluoro-5-metano-sulfonilfenóxi)etil](propil) amina e uso dos mesmos. a presente invenção refere-se a um sal de fórmula iii, um método para a produção do mesmo, bem como usos dos mesmos. fórmula iii, em que x é h ou oh, y é h ou um cátion selecionado do grupo que consiste em li, na e k, é uma ligação simples ou uma ligação dupla, e n é 0,5 ou 1.
BR112021023563A 2019-05-24 2020-05-20 Sais farmaceuticamente aceitáveis de [2-(3-fluoro-5-metano-sulfonilfenóxi)etil](propil) amina e usos dos mesmos BR112021023563A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19176514 2019-05-24
EP20166361 2020-03-27
PCT/EP2020/064046 WO2020239568A1 (en) 2019-05-24 2020-05-20 Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Publications (1)

Publication Number Publication Date
BR112021023563A2 true BR112021023563A2 (pt) 2022-01-04

Family

ID=70682855

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023563A BR112021023563A2 (pt) 2019-05-24 2020-05-20 Sais farmaceuticamente aceitáveis de [2-(3-fluoro-5-metano-sulfonilfenóxi)etil](propil) amina e usos dos mesmos

Country Status (19)

Country Link
US (1) US20220267262A1 (pt)
EP (2) EP4292653A3 (pt)
JP (1) JP2022533433A (pt)
KR (1) KR20220011638A (pt)
CN (1) CN113853369A (pt)
AU (1) AU2020286003A1 (pt)
BR (1) BR112021023563A2 (pt)
CA (1) CA3140805A1 (pt)
CL (1) CL2021003115A1 (pt)
CO (1) CO2021016556A2 (pt)
DK (1) DK3976581T3 (pt)
ES (1) ES2970361T3 (pt)
FI (1) FI3976581T3 (pt)
IL (1) IL288271A (pt)
JO (1) JOP20210312A1 (pt)
MX (1) MX2021014271A (pt)
PT (1) PT3976581T (pt)
SG (1) SG11202112165QA (pt)
WO (1) WO2020239568A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022101227A1 (en) * 2020-11-10 2022-05-19 Integrative Research Laboratories Sweden Ab [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias
WO2024042540A1 (en) * 2022-08-24 2024-02-29 Alkem Laboratories Limited Mesdopetam compositions
WO2024062344A1 (en) 2022-09-21 2024-03-28 Assia Chemical Industries Ltd. Solid state forms of mesdopetam and salts therof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
KR20080036957A (ko) 2005-06-23 2008-04-29 아스트라제네카 아베 위장 질환 치료용 뉴로키닌 수용체 길항제로서의 신규한아제티딘 유도체
US20100292288A1 (en) * 2007-06-08 2010-11-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4`- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
SG193992A1 (en) * 2011-04-19 2013-11-29 Integrative Res Lab Sweden Ab Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission
LT3649124T (lt) * 2017-08-07 2021-06-10 Suven Life Sciences Limited Fluorpiperidino junginiai kaip grynieji 5-ht6 receptorių antagonistai

Also Published As

Publication number Publication date
SG11202112165QA (en) 2021-12-30
PT3976581T (pt) 2024-02-08
WO2020239568A1 (en) 2020-12-03
EP3976581A1 (en) 2022-04-06
EP4292653A2 (en) 2023-12-20
CA3140805A1 (en) 2020-12-03
JOP20210312A1 (ar) 2023-01-30
IL288271A (en) 2022-01-01
US20220267262A1 (en) 2022-08-25
ES2970361T3 (es) 2024-05-28
CO2021016556A2 (es) 2022-01-17
FI3976581T3 (fi) 2024-01-31
MX2021014271A (es) 2022-01-06
JP2022533433A (ja) 2022-07-22
AU2020286003A1 (en) 2021-12-02
CL2021003115A1 (es) 2022-09-30
EP3976581B1 (en) 2023-11-22
EP4292653A3 (en) 2024-04-24
KR20220011638A (ko) 2022-01-28
CN113853369A (zh) 2021-12-28
DK3976581T3 (da) 2024-01-22

Similar Documents

Publication Publication Date Title
BR112021023563A2 (pt) Sais farmaceuticamente aceitáveis de [2-(3-fluoro-5-metano-sulfonilfenóxi)etil](propil) amina e usos dos mesmos
BR112022008919A2 (pt) Composto e método para tratamento de distúrbios psiquiátrico ou neurológico
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
BR112017009601A2 (pt) derivados de aminoácidos e seus usos
BR112019008341A2 (pt) processo para a preparação de pirazolo[1,5-a]pirimidinas e sais dos mesmos
BRPI0708685B8 (pt) composto de 4-oxoquinolina, seu uso e método para produção dos mesmos
BR112013020996A8 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
EA201592055A1 (ru) 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
BR112018001869A2 (pt) método para preparação de ácidos biliares e derivados dos mesmos
BR112014010576B8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
BR112014018702A8 (pt) Composto, cristal, inibidor, medicamento, composição farmacêutica, e, uso de um composto ou sal
BRPI1005812B8 (pt) Composto, composições fungicidas e método para controlar doenças em plantas
MX2016001096A (es) Sales de dasatinib en forma amorfa.
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
BR112013028598A2 (pt) método para promover o crescimento de plantas
BR112014026266A2 (pt) derivado de quinazolidinadiona
AR097545A1 (es) COMPUESTOS A BASE DE PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
BR112014026305A2 (pt) derivado de quinazolidinadiona
BR112014018636A8 (pt) Derivados de benzil sulfonamida úteis como inibidores de mogat-2
BR112014001083A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112021020297A2 (pt) Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune
BR112018014712A2 (pt) processo melhorado para a preparação de osimertinib (azd9291) ou um sal do mesmo e